GlassScriptPhysician profile
Minh Q Tran
NPI 1770534422
$15,792.23
in general payments reported to CMS, 2019-2025
70 companies · $1,541 in 2025
The $1,541 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,112 · 2020: $3,755 · 2021: $1,913 · 2022: $2,181 · 2023: $2,192 · 2024: $2,099 · 2025: $1,541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,807 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,807.11 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,352.55 | 2019-2025 | |
| Novo Nordisk INC | $1,743.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,601.31 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Horizon Therapeutics Plc | $999.66 | 2019-2023 | Krystexxa |
| Amgen INC. | $849.38 | 2019-2025 | Repatha, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $798.78 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $730.37 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $678.73 | 2019-2025 | |
| Lilly USA, LLC | $651.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $607.29 | 2019-2024 | Tradjenta, Jardiance |
| Abbott Laboratories | $530.33 | 2020-2025 | Freestyle Libre 3, Proclaim |
| Amarin Pharma, INC. | $481.24 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $413.20 | 2019-2025 | Belsomra, Gardasil 9, Capvaxive |
| Novartis Pharmaceuticals Corporation | $339.94 | 2022-2025 | |
| Astellas Pharma US INC | $240.43 | 2019-2021 |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minh Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.